GH Research jumps as depression therapy meets mid-stage trial goals

GH Research

03/02/2025 12:51

** Shares of drug developer GH Research  GHRS.O  rise 90% to
$20.14 premarket    
    ** Co's therapy for treatment-resistant depression meets
main goal of mid-stage trial by reducing the severity of the
disease as measured on a widely used scale
    ** GHRS says 57.5% of patients on the therapy, GH001, had
less severe disease at 8 days
    ** GH001 also meets all secondary goals of the trials, GHRS
adds
    ** GHRS rose 20.7% in 2024

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))